Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?

Why SMMT stock is down today

SMMT stock fell 6.59% to $12.47 in early trading on Friday, driven by a sharp intraday selloff following a positive regulatory development. The stock opened at $13.39 but dropped to a session low of $12.07 before recovering slightly to $12.47 at the close of the session. The move came despite recent news of marketing authorization in China for ivonescimab.

What Happened

Summit Therapeutics received marketing authorization in China for the ivonescimab combination in the first-line treatment of advanced squamous non-small cell lung cancer with chemotherapy. This regulatory approval was reported as a significant development for the company. However, the stock experienced a sharp decline during the session, with volume reaching 3.3 million shares, which is 0.7 times the 3-month daily average. The stock traded as low as $12.07 at 9:45 AM ET before partially recovering.

The broader context includes recent upgrades and positive commentary. Leerink Partners upgraded the stock to Market Perform with a $13 price target. Additionally, Summit expanded its clinical development program for ivonescimab into urothelial carcinoma with the initiation of a global trial. Despite these developments, the stock continued to trade near its 52-week low.

What The Data Shows

The stock has traded between $12.25 and $30.05 over the past 52 weeks. It has printed 14 fresh 52-week lows on August 17, 2026. The company remains unprofitable with an EPS of -1.12 and a revenue decline of 100% TTM. Over the last 8 sessions, the stock has declined 2.1% from $13.53 to $13.24. Insider transactions show 5 buys totaling $103.6 million in the last 90 days, with the most recent purchases made on June 12 by two co-CEOs and on June 4 by the COO and CFO.

What To Watch

The stock does not have an upcoming earnings date listed. Investors may monitor the breadth of coverage and any further developments in the clinical trials or regulatory approvals for ivonescimab.